Related Experiment Video
Updated: May 14, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Abstract:
Consolidation of the specialty pharmacy business indicates a repositioning to buy new market channels, reduce costs, and compete in a burgeoning market. The challenge for SP is to prove its value to payers. Some companies are doing that on the basis of price or by offering care management services. Here's a look at a business in transition as it redefines itself for the biologics era.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
